know more about us

Prof Kenneth Cusi, USA discusses the role of diabetologists in screening for NASH

Why are PPAR agonists a promising option for the management of NASH ?

Lipotoxicity in NASH

Prof Szabo, USA discusses the progresses of the quest of biomarkers in NASH

Learn more about the burden of the disease, Prof Sven Francque, Belgium

What are the current definitions ? Prof Abdelmalek, USA

An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA

Is NASH only about the liver ?